{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:21:24Z","timestamp":1787775684862,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This cross-sectional study aimed to assess the frequency of potential drug\u2013drug interactions (DDIs) and demographic correlates of moderate and major DDIs among patients with hematologic cancer at a referral hematology hospital in Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this study, for 6 months, all patients suffering from hematologic cancers admitted to the tertiary oncology hospital, Omid, Isfahan, were considered. Data from all medications prescribed to patients during hospitalization were analyzed using the online Lexicomp\n                      <jats:sup>\u00ae<\/jats:sup>\n                      drug interaction checker, recording all interactions classified by risk level: C, D, or X.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>A total of 674 DDIs were detected in 109 patients. The prevalence of treatments with at least one clinically relevant interaction was 95%, being 57.9% for those at level C and 31.5% for levels D and X. According to the frequency, the main interaction was between aprepitant and corticosteroids, followed by the interaction between aprepitant and vincristine. The most common interaction between antineoplastic agents was between doxorubicin and cyclophosphamide. In terms of mechanism, most of DDIs (54.9%) were pharmacodynamics. Only the number of administered medications was associated with DDI occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Potential DDIs of moderate to major severity are common among patients with hematologic malignancies. This underscores the importance of implementing different strategies to mitigate this clinically significant risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_40_24","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T05:02:06Z","timestamp":1725944526000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Potential Drug Interactions in Hospitalized Hematologic Cancer Patients: New Update with New Chemotherapy Regimens"],"prefix":"10.4103","volume":"12","author":[{"given":"Tahereh","family":"Gholipourshahraki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Aria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cancer Prevention Research Center, Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology-Oncology Section, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Moghadas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Moghaddas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"R1-20240911","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/07357900601063766","article-title":"A systematic review on drug interactions in oncology","volume":"24","author":"Riechelmann","year":"2006","journal-title":"Cancer Invest"},{"key":"R2-20240911","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-017-2232-4","article-title":"Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions:A prospective cohort study","volume":"73","author":"Muhi\u010d","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R3-20240911","doi-asserted-by":"crossref","first-page":"e12944","DOI":"10.1111\/ecc.12944","article-title":"Drug interactions with oral antineoplastic drugs:The role of the pharmacist","volume":"28","author":"Riu-Viladoms","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R4-20240911","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00280-013-2162-5","article-title":"Potential drug-drug interactions at a referral hematology-oncology ward in Iran:A cross-sectional study","volume":"71","author":"Hadjibabaie","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R5-20240911","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1097\/MPH.0000000000001346","article-title":"Potential drug-drug interactions at a referral pediatric oncology ward in Iran:A cross-sectional study","volume":"41","author":"Tavousi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R6-20240911","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1078155217717324","article-title":"Prevalence study on potential drug-drug interaction in cancer patients in Piacenza hospital's onco-haematology department","volume":"24","author":"Vecchia","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"R7-20240911","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s11096-014-0011-1","article-title":"Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients","volume":"36","author":"Fern\u00e1ndez de Palencia Espinosa","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R8-20240911","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","article-title":"Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy","volume":"20","author":"Ismail","year":"2020","journal-title":"BMC Cancer"},{"key":"R9-20240911","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1177\/1078155220963212","article-title":"Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors","volume":"27","author":"Bibi","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"R10-20240911","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1078155220910209","article-title":"Potential drug-drug interactions in hospitalized cancer patients:A report from the middle-East","volume":"27","author":"Moghaddas","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"R11-20240911","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/djk130","article-title":"Potential drug interactions and duplicate prescriptions among cancer patients","volume":"99","author":"Riechelmann","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R12-20240911","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1470-2045(10)70105-4","article-title":"Drug interactions in childhood cancer","volume":"12","author":"Haidar","year":"2011","journal-title":"Lancet Oncol"},{"key":"R13-20240911","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00280-004-0998-4","article-title":"Potential for drug interactions in hospitalized cancer patients","volume":"56","author":"Riechelmann","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"R14-20240911","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/jrptps.JRPTPS_67_18","article-title":"Evaluation of potential drug-drug interactions in patients with hematologic malignancies at a referral hematology and oncology hospital:A single-center experience","volume":"8","author":"Ataei","year":"2019","journal-title":"J Rep Pharm Sci"},{"key":"R15-20240911","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/0022-3859.85207","article-title":"A study of drug-drug interactions in cancer patients of a South Indian tertiary care teaching hospital","volume":"57","author":"Kannan","year":"2011","journal-title":"J Postgrad Med"},{"key":"R16-20240911","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1345\/aph.1L255","article-title":"Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents:Profiling and comparison of two drug compendia","volume":"42","author":"Wong","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R17-20240911","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1007\/s00520-019-05221-1","article-title":"Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea","volume":"28","author":"Song","year":"2020","journal-title":"Support Care Cancer"},{"key":"R18-20240911","first-page":"175","article-title":"Potential of drug interactions among hospitalized cancer patients in a developing country","volume":"12","author":"Tavakoli-Ardakani","year":"2013","journal-title":"Iran J Pharm Res"},{"key":"R20-20240911","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ajhp\/61.4.380","article-title":"Evaluation of personal digital assistant software for drug interactions","volume":"61","author":"Barrons","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"R21-20240911","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s11096-010-9445-2","article-title":"Evaluation of three brands of drug interaction software for use in intensive care units","volume":"32","author":"Reis","year":"2010","journal-title":"Pharm World Sci"},{"key":"R22-20240911","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgo.2017.07.015","article-title":"Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy:Observational single-center study of 122 patients","volume":"9","author":"Leger","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"R23-20240911","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1078155216664201","article-title":"Potential drug-drug interactions in hospitalised haematological patients","volume":"23","author":"Fern\u00e1ndez de Palencia Espinosa","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R24-20240911","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology:How common are they?","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann Oncol"},{"key":"R25-20240911","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/1471-2407-10-679","article-title":"Potential drug interactions and duplicate prescriptions among ambulatory cancer patients:A prevalence study using an advanced screening method","volume":"10","author":"van Leeuwen","year":"2010","journal-title":"BMC Cancer"},{"key":"R26-20240911","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11096-011-9574-2","article-title":"Prevalence of potential drug-drug interactions in bone marrow transplant patients","volume":"33","author":"Guastaldi","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"R27-20240911","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ejhpharm-2014-000449","article-title":"Potential drug interactions and side effects in an outpatient oncology clinic:A retrospective descriptive study","volume":"21","author":"Bayraktar-Ekincioglu","year":"2014","journal-title":"Eur J Hosp Pharm"},{"key":"R28-20240911","first-page":"10","article-title":"Observational study of drug-drug interactions in oncological inpatients","volume":"42","author":"D\u00edaz-Carrasco","year":"2018","journal-title":"Farm Hosp"},{"key":"R29-20240911","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-010-0979-y","article-title":"Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database","volume":"67","author":"Strandell","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-20240911","first-page":"271","article-title":"Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system","volume":"237","author":"Dodion","year":"1986","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_40_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:39:05Z","timestamp":1787773145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_40_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_40_24","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2024-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}